Riluzole (RP 54274) is a potent neuroprotective agent with anticonvulsant,
sedative, and anti-ischemic properties. It is currently used in the treatme
nt of amyotrophic lateral sclerosis. This article reports that riluzole is
an activator of TREK-1 and TRAAK, two important members of a new structural
family of mammalian background K+ channels with four transmembrane domains
and two pore regions. Whereas riluzole activation of TRAAK is sustained, a
ctivation of TREK-1 is transient and is followed by an inhibition. The inhi
bitory process is attributable to an increase of the intracellular cAMP con
centration by riluzole that produces a protein kinase A-dependent inhibitio
n of TREK-1. Mutants of TREK-1 lacking the Ser residue where the kinase A p
hosphorylation takes place are activated in a sustained manner by riluzole.
TRAAK is permanently activated by riluzole because, unlike TREK-1, it lack
s the negative regulation by cAMP.